HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US Pandemic Emergency Manufacturing Act Submitted Again By Warren, Schakowsky

Executive Summary

Pandemic Emergency Manufacturing Act authorizes federal government and its contractors to make personal protective equipment, Rx drugs, ventilators, respirators and vaccines as well tests for coronavirus, including OTC products, to address the public health emergency.

You may also be interested in...



CBD Regulation Bill Filed In US House Again; VMS In Pre-Tax Savings Accounts In First Senate Vote

Hemp-Derived CBD bill either provides exact solution US needs for lawful use of cannabinoids as dietary ingredients or falls well short, depending on the trade group. Legislation to expand health savings accounts to include vitamin, mineral and supplement products reached Senate floor vote before failing.

US Supply Of OTC COVID-19 Tests Gets Boost Through $231.8M Contract For Australian Firm

Biden administration seems to be betting Elluve's OTC at-home antigen diagnostic test will be a game changer in helping stop the spread of the coronavirus.

OTC Diagnostics Forecast: Growing With Pandemic But High Bar For Approval Could Slow Spread

Sample-collection kit and testing firms acknowledge regulatory approval for OTC sales can be as complicated as the technology behind their products. But consumers have OTC access to numerous at-home collection kits for tests for indications of diseases or medical conditions as well as for genealogy. Kits approved for testing for influenzas or other infections also should become available OTC, say industry stakeholders.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151000

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel